Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.74 |
| ▸ | CASP1 | P29466 | 4/20 | 0.74 |
| ▸ | CASP4 | P49662 | 4/20 | 0.74 |
| ▸ | CASP5 | P51878 | 4/20 | 0.74 |
| ▸ | MAPT | P10636 | 3/20 | 0.74 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.74 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.74 |
| ▸ | MEN1 | O00255 | 2/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.74 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.74 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.74 |
| ▸ | RGS12 | O14924 | 1/20 | 0.74 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.74 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.74 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.74 |
| ▸ | TSHR | P16473 | 1/20 | 0.74 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.74 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.74 |
| ▸ | GLA | P06280 | 1/20 | 0.74 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL10720129 | 0.99 | ALDH1A1 (0.73) | ALDH1A1CASP1CASP4CASP5MAPT | |
| SCHEMBL10724112 | 0.95 | ALDH1A1 (0.67) | ALDH1A1CASP1CASP4CASP5MAPT | |
| SCHEMBL31066922 | 0.87 | ALDH1A1 (0.56) | ALDH1A1CASP1CASP4CASP5MAPT | |
| Hydrochloric Acid SCHEMBL9725003 | 0.85 | CASP1 (0.54) | ALDH1A1CASP1CASP4CASP5MAPT | |
| SCHEMBL4879271 | 0.85 | CASP1 (1.00) | ALDH1A1CASP1CASP4CASP5MAPT | |
| SCHEMBL24125220 | 0.85 | CASP1 (1.00) | ALDH1A1CASP1CASP4CASP5MAPT | |
| SCHEMBL14360999 | 0.85 | CASP1 (1.00) | ALDH1A1CASP1CASP4CASP5MAPT | |
| SCHEMBL25994360 | 0.85 | CASP1 (1.00) | ALDH1A1CASP1CASP4CASP5MAPT | |
| Hydrochloric Acid SCHEMBL10721988 | 0.84 | CASP1 (0.98) | ALDH1A1CASP1CASP4CASP5MAPT | |
| SCHEMBL9202083 | 0.84 | ALDH1A1 (0.53) | ALDH1A1CASP1CASP4CASP5MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250064834-A1 | COMPOSITIONS AND METHODS FOR TREATMENT AND PREVENTION OF DISEASES UTILIZING TIRILAZAD SALTS | PRENDERGAST PATRICK T (IE) | 2025-02-27 | — | — | US | claimed |
| EP-4475853-A1 | COMPOSITIONS AND METHODS FOR TREATMENT AND PREVENTION OF DISEASES UTILIZING TIRILAZAD SALTS | Prendergast, Patrick T. (IE) | 2024-12-18 | — | — | EP | claimed |
| CN-118804754-A | Compositions and methods for treating and preventing diseases using tirapazad salts | 帕特里克·T·普伦德加斯特 | 2024-10-18 | — | — | CN | claimed |
| US-20240285653-A1 | COMPOSITIONS AND METHODS FOR TREATMENT AND PREVENTION OF DISEASES UTILIZING TIRILAZAD SALTS | PRENDERGAST PATRICK T (AU) | 2024-08-29 | — | — | US | claimed |
| WO-2023154647-A1 | COMPOSITIONS AND METHODS FOR TREATMENT AND PREVENTION OF DISEASES UTILIZING TIRILAZAD SALTS | PRENDERGAST PATRICK T (IE) | 2023-08-17 | — | — | WO | claimed |
| US-20050054646-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and an antioxidant agent for the treatment of central nervous system disorders | PHARMACIA CORPORATION | 2005-03-10 | — | — | US | claimed |
| WO-2005016243-A2 | COMPOSITIONS OF A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND AN ANTIOXIDANT AGENT FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | PHARMACIA CORPORATION (US) | 2005-02-24 | — | — | WO | claimed |
| EP-0238545-B1 | C20 THROUGH C26 AMINO STEROIDS | UPJOHN CO (US) | 1995-11-15 | — | — | EP | claimed |
| EP-0263213-B1 | C20 Through C26 amino steroids | UPJOHN CO (US) | 1995-09-06 | — | — | EP | claimed |
| US-5175281-A | Antiulcer, antiinflammatory, antiischemic, antiallergen, antisecretory, wound healing agents; cardiovascular disorders | THE UPJOHN COMPANY (US) | 1992-12-29 | — | — | US | claimed |
| EP-0263213-A1 | C20 Through C26 amino steroids | THE UPJOHN COMPANY (US) | 1988-04-13 | — | — | EP | claimed |
| EP-0238545-A1 | C 20? THROUGH C 26? AMINO STEROIDS. | UPJOHN CO (US) | 1987-09-30 | — | — | EP | claimed |
| WO-1987001706-A2 | C20 THROUGH C26 AMINO STEROIDS | THE UPJOHN COMPANY (US) | 1987-03-26 | — | — | WO | claimed |
| US-20250064834-A1 | COMPOSITIONS AND METHODS FOR TREATMENT AND PREVENTION OF DISEASES UTILIZING TIRILAZAD SALTS | PRENDERGAST PATRICK T (IE) | 2025-02-27 | — | — | US | disclosed |
| EP-4475853-A1 | COMPOSITIONS AND METHODS FOR TREATMENT AND PREVENTION OF DISEASES UTILIZING TIRILAZAD SALTS | Prendergast, Patrick T. (IE) | 2024-12-18 | — | — | EP | disclosed |
| CN-118804754-A | Compositions and methods for treating and preventing diseases using tirapazad salts | 帕特里克·T·普伦德加斯特 | 2024-10-18 | — | — | CN | disclosed |
| CN-1118580-C | Characterization of polypeptides | BRAX GENOMICS LTD (GB) | 2003-08-20 | — | — | CN | disclosed |
| EP-1027454-A1 | CHARACTERISING POLYPEPTIDES | Brax Group Limited (GB) | 2000-08-16 | — | — | EP | disclosed |
| CN-1244218-A | Characterising polypeptides | BRAX GENOMICS LTD (GB) | 2000-02-09 | — | — | CN | disclosed |
| WO-1998032876-A1 | CHARACTERISING POLYPEPTIDES | BRAX GROUP LIMITED (GB) | 1998-07-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054646-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and an antioxidant agent for the treatment of central nervous system disorders | TXNRD2, PRDX5, PTGS2 | ALDH1A1 730/4885CASP1 2973/4885CASP4 3093/4885 |
| US-20240285653-A1 | COMPOSITIONS AND METHODS FOR TREATMENT AND PREVENTION OF DISEASES UTILIZING TIRILAZAD SALTS | TTR, MTPN, CYP24A1 | ALDH1A1 1494/4885CASP1 818/4885CASP4 1557/4885 |
| US-20250064834-A1 | COMPOSITIONS AND METHODS FOR TREATMENT AND PREVENTION OF DISEASES UTILIZING TIRILAZAD SALTS | CYP24A1, IL23R, IL17A | ALDH1A1 586/4885CASP1 838/4885CASP4 1450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.